Showing 15 posts of 80 posts found.

Melanoma market to reach $7.4bn by 2029

April 30, 2021
Medical Communications melanoma

A report from GlobalData, Melanoma – Global Drug Forecast and Market Analysis to 2029, has predicted the melanoma industry will …


Novartis’ Tafinlar/Mekinist combo improves five-year relapse-free survival in new Phase 3 data

September 17, 2020
Research and Development Novartis, Tafinlar, mekinist, melanoma

Novartis has unveiled promising new Phase 3 data for its combination of Tafinlar (dabrafenib) with Mekinist (trametinib) in the treatment …


Scotland approves targetted combination therapy for advanced melanoma

February 11, 2020
Manufacturing and Production NHS, SMC, Scotland, UK, advanced melanoma, melanoma

The Scottish Medicines Consortium (SMC) has approved targeted combination therapy for the treatment of adult patient with unresectable or metastatic …


Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma

December 16, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …


EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma

September 25, 2019
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …


MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma

May 14, 2019
Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma

MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …

Living with melanoma after surgery

February 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, melanoma, patient experience, pharma

Dr Elizabeth Walmsley was left lost when she received her melanoma diagnosis. Thankfully, through perseverance and the advice of friends …

Smoking may limit immune system’s ability to fight cancer, study shows

February 18, 2019
Sales and Marketing Cancer, cancer research, immune system, immunology, melanoma, oncology, smoking

Smoking may limit the body’s ability to fight melanoma, according to a study published in the journal Cancer Research. The …


NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma

January 21, 2019
Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma

Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …


Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund

November 30, 2018
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …

MSD’s Keytruda to treat melanoma in England on the Cancer Drugs Fund

November 19, 2018
Sales and Marketing England, MSD, NHS, UK, keytruda, melanoma, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it …

BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients

October 22, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo

American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …

NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma

September 17, 2018
Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma

NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …


BMS’ Opdivo fails to win over NICE as adjuvant melanoma therapy

September 10, 2018
Sales and Marketing BMS, NHS, NICE, melanoma, opdivo, pharma

Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an …

Latest content